Pefachrome® FXIIa 6017, Chromogenic Substrate for Factor XIIa
Application:
Highly sensitive chromogenic peptide substrate for factor XIIa. Determination of factor XIIa activity for research, in-process and quality control.
Formula: H-D-CHA-Gly-Arg-pNA · 2AcOH
MW: 624.7
Principle: H-D-CHA-Gly-Arg-pNA + FXIIa ==> H-D-CHA-Gly-Arg-OH + pNA + FXIIa
KM: 0.8 mM
vmax: 3.14 µmol/min
Solubility: Up to 4 mM in H2O
Storage:
May be used by the expiry date given on the label when stored unopened, protected from moisture, in the dark, 2-8°C. Avoid contamination of the reagents by micro-organisms. Shipment of product does not require cooling during the time of transportation.
Material required but not provided:
Buffer, NaCl, reference material, dist. H2O, Pefabloc® PK, Kalliplastin®
Buffer:
50 mM Tris-imidazole buffer pH 7.9, 150 mM NaCl
Assay 1:
Suggested protocol for the determination of factor XIIa activity:
0.700 ml buffer
0.100 ml factor XIIa (0.2 units/ml)
0.200 ml Pefachrome®6017 4 mM
==> Determination of ∆OD/min at 405 nm
Assay 2:
Suggested protocol for the determination of factor XIIa activity (FXII activated by Kalliplastin®) using Pefachrome®6017 and a selective synthetic inhibitor of plasma kallikrein (Pefabloc® PK):
0.100 ml citrated plasma (diluted 1:5 with NaCl)
0.200 ml Kalliplastin® (20 µg/ml, Pentapharm Ltd.)
> incubate for 1 min at 37 °C
0.500 ml buffer
0.100 ml Pefabloc® PK 0.2 mM
0.100 ml Pefachrome®6017 2 mM
==> Determination of ∆OD/min at 405 nm
Category: Research use only
Type: Substrate
Product Availability: Germany, Israel and Egypt
Manufacturer: DSM Nutritional Products Ltd. Branch Pentapharm, Switzerland
For more information please click .pdf icon below.
Pefachrome FXIIa 6017
Chromogenic Substrate for Factor XIIa
Artikelnr.: 808145
Einheit: 3x10µMol
Code: 081-45
Hersteller: Pentapharm AG
Reference
- Stürzebecher J, Svendsen L, Eichenberger R, Markwardt F.
A new assay for the determination of factor XII in plasma using a chromogenic substrate and a selective inhibitor of plasma kallikrein.
Thromb Res 1989; 55: 709-15.